Optimum is a proud sponsor of ON Helix. This one-day conference will address key bio innovation trends, from developments in life science and technology research to their translation into new diagnostics, prevention tools or treatments. Delegates and Supporters will connect with the One Nucleus network to explore New Horizons for Bio Innovation. ON Helix Key […]
Alys Pharmaceuticals Announces Dosing of First Patient in Phase IIa Trial of ALY-101 for Alopecia Areata Alys Pharmaceuticals announced that the first patient has been dosed in its Phase IIa trial of ALY-101 in patients suffering from Alopecia Areata. ALY-101 is formulated as an intradermal injectable and its unique siRNA platform, developed with Nobel Prize […]
Back in mid-January Optimum’s Hot Topics column took a look at life expectancy data and asked the rather depressing question: “Will you live longer than your parents – or not?” Why so downbeat? Because besides stalling life expectancy figures, a slew of other data also seemed to hint that longevity might have peaked: steadily growing […]
Sofinnova Partners exceeds target with €165m biotech acceleration fund close, Europe’s largest, with strong Pharma support Sofinnova Partners announced the final close of Sofinnova Biovelocita II. The fund has exceeded its target, successfully raising €165M, with substantial backing from the top global pharmaceutical companies, including Amgen, Bristol Myers Squibb, and Pfizer Ventures. iOnctura strengthens leadership […]
Like other industries, Biotech and Pharma are viewing the Trump administration with some trepidation. One concern – among many – is whether job cuts instituted by the US’s Department of Government Efficiency (DOGE), led by Elon Musk, will slow down the rate of drug approvals. Among the agencies hit are the Food and Drugs Administration […]
